Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss from continuing operations	$ (3,392,305)	$ (6,857,700)
Loss from discontinued operations, net of tax	0	(1,252,276)
Gain on sale of discontinued operations		1,534,479
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations		(1,534,479)
Stock-based compensation	309,152	375,169
Depreciation and amortization of intangible assets	46,136	47,061
Amortization of right of use assets	93,174	68,779
Change in fair value of earnout liabilities	29,630	0
Amortization of debt discount	0	19,549
Loss on forward purchase agreement	0	4,280,314
Changes in operating assets and liabilities:
Accounts receivable	26,155
Inventory	222,210	(113,872)
Prepaid expenses	321,096	597,108
Assets available for sale		4,662,980
Accounts payable	258,791	(321,816)
Accrued expenses and other liabilities	592,530	(1,259,808)
Lease liability	(95,712)	(70,399)
Liabilities available for sale		(2,389,343)
Net cash used in operating activities	(1,589,143)	(2,214,254)
Cash flows from investing activities
Cash paid for Elevai Acquisition transaction costs	(150,000)
Cash paid for offering costs	(15,000)
Cash paid in AxoBio Disposition		(748,796)
Net cash used in investing activities	(165,000)	(748,796)
Cash flows from financing activities:
Proceeds from issuance of Common Stock, net of costs	3,397,476	2,687,225
Proceeds from issuance of loans	0	31,538
Repayment of loans	(249,273)	(469,899)
Net cash provided by financing activities	3,148,203	2,248,864
Net increase (decrease) in cash	1,394,060	(714,186)
Cash - beginning of the period	157,139	2,912,461
Cash - end of the period	1,551,199	2,198,275
Supplemental cash flow information:
Interest paid	7,554	14,830
Non-cash financing activity:
Fair value of shares issued in Elevai Acquisition	660,805
Consideration payable	67,742
Earnout liabilities in Elevai Acquisition	301,633
Insurance premium financing agreement	24,787
Unpaid deferred offering costs	$ 50,000
Fair value of shares received in AxoBio Disposition		23,456,179
Net assets sold in AxoBio Disposition		21,921,697
Common Stock issued in connection with conversion of Notes		$ 848,500